Pages that link to "Q44092763"
Jump to navigation
Jump to search
The following pages link to Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival (Q44092763):
Displaying 50 items.
- MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine (Q24302440) (← links)
- Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy (Q24795468) (← links)
- Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer (Q27851727) (← links)
- Thymidylate synthase pharmacogenetics (Q27863339) (← links)
- Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase (Q28207327) (← links)
- Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. (Q28303251) (← links)
- Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection (Q28346756) (← links)
- A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil (Q28352447) (← links)
- Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors (Q28533752) (← links)
- Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway (Q30834530) (← links)
- Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma. (Q31098180) (← links)
- Determinants of prognosis and response to therapy in colorectal cancer (Q31935218) (← links)
- Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer (Q33317139) (← links)
- ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel (Q33327609) (← links)
- Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker (Q33337970) (← links)
- Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. (Q33372119) (← links)
- A metabonomic approach to chemosensitivity prediction of cisplatin plus 5‐fluorouracil in a human xenograft model of gastric cancer (Q33829758) (← links)
- 19F-MRS studies of fluorinated drugs in humans (Q33852961) (← links)
- Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer (Q33884698) (← links)
- 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development (Q33925505) (← links)
- Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients (Q33944623) (← links)
- Adjuvant therapy for gastric cancer: a reality at last (Q34082745) (← links)
- Colorectal cancer staging and adjuvant chemotherapy (Q34182099) (← links)
- The oral fluorinated pyrimidines (Q34211250) (← links)
- Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. (Q34224839) (← links)
- Recent advances in the treatment of gastric cancer (Q34385364) (← links)
- Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation (Q34620545) (← links)
- Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. (Q34743494) (← links)
- Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? (Q34847802) (← links)
- MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells (Q34894800) (← links)
- Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis (Q34989932) (← links)
- Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer (Q35000906) (← links)
- DNA repair and cisplatin resistance in non-small-cell lung cancer (Q35006234) (← links)
- Future potential of thymidylate synthase inhibitors in cancer therapy (Q35011904) (← links)
- Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo (Q35048000) (← links)
- Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. (Q35083755) (← links)
- Curative treatment of gastric cancer: towards a multidisciplinary approach? (Q35097713) (← links)
- Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update (Q35123014) (← links)
- Pharmacogenomics: road to anticancer therapeutics nirvana? (Q35551155) (← links)
- Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. (Q35615776) (← links)
- Antimetabolite Treatment for Pancreatic Cancer (Q35826334) (← links)
- Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review (Q35862225) (← links)
- Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy (Q35875892) (← links)
- Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer (Q35878616) (← links)
- A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma (Q36097126) (← links)
- Genetic factors influencing pyrimidine-antagonist chemotherapy. (Q36205831) (← links)
- Lynch syndrome (hereditary non-polyposis colorectal cancer): current concepts and approaches to management (Q36259687) (← links)
- From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates (Q36354734) (← links)
- Tailor-made chemotherapy for non-small cell lung cancer patients (Q36430761) (← links)
- Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question (Q36503388) (← links)